ArticleInternational journal of clinical and experimental pathology2026
Coexisting early gastric adenocarcinomas of pyloric gland-type and intestinal-type with different genetic mutations in the setting of autoimmune gastritis.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a 58-year-old female with no significant symptoms who was found to have two distinct gastric lesions during routine endoscopy: a 15 mm lesion in the fundus, diagnosed as gastric adenocarcinoma of pyloric gland mucosa-type (GA-PGM), and a 30 mm cauliflower-like mass in the gastric body, identified as well-differentiated tubular adenocarcinoma with gastrointestinal mixed type (GA-TAC), accompanied by multifocal neuroendocrine cell hyperplasia in the background of autoimmune gastritis (AIG). Molecular analysis revealed distinct genetic alterations between the two tumors despite arising within the same gastric background: GA-PGM harbored a KRAS p.Q61H mutation and MDM2 amplification, whereas GA-TAC showed a KRAS p.G12D mutation along with STK11 and additional alterations. This case reports the unusual coexistence of GA-PGM and GA-TAC in the setting of AIG, with the two lesions presenting distinct clinicopathologic and molecular characteristics. Our findings support the hypothesis that these two tumor subtypes originate from distinct metaplastic cell lineages through independent tumorigenic pathways, and add to the limited clinical evidence for the rare entity, GA-PGM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.